Cargando…

Long-term treatment of rheumatoid arthritis with adalimumab

Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased risk of morbidity related to comorbid conditions and substantial socioeconomic costs. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine known to h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murdaca, Giuseppe, Spanò, Francesca, Puppo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074792/ https://www.ncbi.nlm.nih.gov/pubmed/27790023 http://dx.doi.org/10.2147/OARRR.S32582

Ejemplares similares

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Certolizumab in the long-term treatment of rheumatoid arthritis
por: Khan, Abdul, et al.
Publicado: (2011)

Long-term use of adalimumab in the treatment of rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2009)

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
por: Kotaniemi, Kaisu, et al.
Publicado: (2011)

Successful Treatment of Pseudoseptic Arthritis Contained Massive Purulent Fluid with Adalimumab in Rheumatoid Arthritis
por: Chung, Chong Hyuk, et al.
Publicado: (2020)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis
por: Bergström, Ulf, et al.
Publicado: (2018)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
por: Nguyen, Dao X., et al.
Publicado: (2018)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis
por: Cacciapaglia, Fabio, et al.
Publicado: (2022)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Immunoregulatory Role of HLA-G in Allergic Diseases
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
por: Kobak, Senol, et al.
Publicado: (2014)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
por: Gissel, C., et al.
Publicado: (2017)

Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices
por: Sakthiswary, R., et al.
Publicado: (2012)

Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia
por: Deakin, Claire T., et al.
Publicado: (2023)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q0pclapmpkcphei72b0q724q4l